Hook & thesis:
Trulieve Cannabis (TCNNF) is a multi-state operator built on a retail-first distribution model and vertically integrated production. Management has demonstrated an ability to sustain attractive gross margins and convert sales into EBITDA at scale. With the stock trading at roughly $6.13 and a market cap near $1.18 billion, the risk-reward looks favorable if the company continues to monetize its footprint, expand same-store sales and benefit from industry reclassification and M&A tailwinds.
The trade here is a long bias: buy into improving fundamentals and a regulatory tailwind that materially lowers operating friction for state-legal cannabis businesses. This is a structural, catalyst-driven position sized for a long-term horizon (180 trading days) with defined entry, target and stop-loss levels below.
The business and why the market should care
Trulieve operates as a vertically integrated cannabis company: it cultivates, manufactures and sells medical (and adult-use where permitted) products through its branded stores and home delivery. The company's CEO, Kimberly A. Rivers, has publicly framed the firm as a retail-led MSO focused on operational discipline and steady rollouts.
Why investors should care: scale and margins. Independent research noted by sell-side coverage forecasts roughly $1.20 billion in 2024 revenue for Trulieve with a 55.1% gross margin and a ~24.9% EBITDA margin, implying an EBITDA run-rate near $298.8 million. Those metrics, if sustained or improved, put Trulieve in a different bucket than lower-margin operators and make it an obvious consolidator candidate in a market where larger players can deploy capital accretively.
What the numbers say
- Current price: $6.13. The stock opened today at $5.92, traded as high as $6.47, and closed intraday near current levels.
- Market capitalization: $1.18 billion.
- 52-week range: $3.02 to $11.83 - the stock has retraced substantially from late-2025 highs but is well above its April 2025 lows.
- Valuation signals: PB ratio ~1.06 and a negative PE (PE = -10.52) consistent with a company that is investing in growth or still cycling through noncash items at the net income line while producing strong operating margins.
- Liquidity & investor behavior: average volume ~238k (2-week average), recent average 30-day volume ~199.6k. Short interest has trended materially lower in recent settlement snapshots (most recent reported short interest ~19,404 shares), and short-volume data shows regular intraday short activity but days-to-cover remains 1, reflecting a relatively shallow borrow base relative to daily flows.
- Technicals: the 10-day SMA is $6.26 and 20-day SMA $6.42; 50-day SMA sits at $7.44. RSI at ~41.9 indicates the stock is not overbought and has room to appreciate. MACD shows a small bullish histogram, signaling nascent upside momentum.
Valuation framing
At a ~$1.18 billion market cap and the 2024 revenue estimate of ~$1.20 billion, Trulieve is trading near 1.0x revenue on a forward-looking basis (using the cited 2024 revenue estimate). On an EBITDA basis, using the projected ~$298.8 million figure, the company's enterprise value multiple would look materially cheaper than many growth-stage peers, particularly if net leverage is manageable (note: balance sheet detail not embedded here). Independent coverage has suggested a blended fair value as high as $15.29 per share which, if realized over time, implies meaningful upside from current levels.
Qualitatively, Trulieve's valuation is supported by: (1) strong gross margins (55%+ in sell-side estimates), (2) a retail-first, vertically integrated model that preserves margin capture, and (3) potential relief from federal policy that can improve banking access and reduce compliance costs. The counterbalance is that cannabis equities still trade with a policy and execution risk premium; as a result, multiples for MSOs will likely remain compressed until further normalization of capital markets and federal clarity.
Catalysts (events that could re-rate the stock)
- Federal policy - continued rollout of Schedule III implementation and related banking/regulatory guidance that eases operating friction for state-legal operators.
- Quarterly results that validate margin sustainability - beats on revenue and margin that confirm the sell-side estimates of 55% gross and ~25% EBITDA margin.
- M&A activity - Trulieve is a logical consolidator; accretive deals or even market commentary about strategic purchases could lift the multiple.
- Retail expansion - new store openings and same-store-sales acceleration in existing markets.
The trade plan (actionable)
Horizon: long-term (180 trading days). This is not a quick scalp. The thesis requires time for margin realization, policy moves and/or M&A to be priced into the equity.
| Metric | Value |
|---|---|
| Entry price | $6.13 |
| Stop loss | $5.25 |
| Target price | $9.00 |
| Time horizon | Long term (180 trading days) |
Rationale: Entry at $6.13 puts you below short-term resistance around the 10-20 day moving averages while capturing a base in the $5.90–$6.50 intraday band. The $5.25 stop sits below recent support and gives the position room for normal volatility, while a $9.00 target reflects a conservative re-rating toward mid-cycle multiples and still well below some sell-side fair-value outputs. This plan favors a disciplined ramp rather than aggressive averaging; if you add, do so only on clear fundamental deterioration or technical support re-test near the stop level.
Risk profile - what could go wrong
- Regulatory reversal or delay: Federal or state-level regulatory setbacks, or slower implementation of Schedule III policies, could keep credit and banking frictions elevated and pressure margins.
- Execution risk: Margin expansion in estimates assumes operating leverage; a failure to convert SG&A or cost-synergies risks compressing EBITDA and valuation.
- Competitive pressure: Larger MSOs and regional operators can compete on price or distribution, which may blunt same-store sales growth and margins.
- Capital markets & access to funding: If appetite for cannabis M&A or growth capital weakens, Trulieve may face higher financing costs or limited inorganic growth options.
- Volatility & liquidity: OTC-traded cannabis stocks can gap on headlines; the average daily volume is modest relative to tier-1 names, so entries/exits may experience slippage in stressed markets.
Counterarguments
There is a reasonable counterargument that the stock still prices in regulatory and execution risk and that management needs to prove sustainable free cash flow conversion before multiples expand. The negative PE (-10.52) signals net loss at the current GAAP level, and investors could reasonably demand a longer track record of net income or deleveraging before assigning premium multiples associated with higher-margin estimates. In short, patience may be required; if margins disappoint or federal policy momentum stalls, downside could extend to prior support near $3.02.
Conclusion - clear stance and what would change my mind
Stance: I am constructive on Trulieve and recommend a long position with the trading plan above: entry $6.13, stop $5.25 and target $9.00 over a 180-trading-day horizon. The trade banks on margin durability, the benefits of scale in a consolidating sector, and favorable regulatory momentum that should improve operating cash flow and investor sentiment.
What would change my mind: a material miss on quarterly revenue or EBITDA relative to the structural estimates (~$1.2B revenue / ~$299M EBITDA), a public statement from regulators reversing or stalling Schedule III implementation, or evidence of sustained margin compression at the retail or wholesale level would force a reassessment and likely a reduction in conviction.
Key points
- Trulieve trades at roughly $6.13 with a market cap near $1.18B and appears inexpensive on implied forward revenue and EBITDA multiples using current sell-side estimates.
- Projected 2024 metrics show a path to high gross margins (~55%) and strong EBITDA (~25%), which supports a higher multiple if executed.
- Regulatory tailwinds and potential M&A are the primary catalysts to re-rate the business.
- Defined trade: entry $6.13, stop $5.25, target $9.00 for a long-term (180 trading days) position.
Trade actively, size positions to risk tolerance, and keep the stop-loss firm. This is a long idea built on execution and policy—both of which deserve monitoring through the trade horizon.